Candida peritonitis

Candida peritonitis

peritonitis caused by a species of Candida, usually as a complication of peritoneal dialysis, with symptoms that include abdominal pain with or without mild fever, nausea, and vomiting.
Mentioned in ?
References in periodicals archive ?
Treatment of patients with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses.
Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA) for the use of MYCAMINE (micafungin sodium) for injection by intravenous infusion for the treatment of pediatric patients four months and older with candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses, esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplants (HSCT).
Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses
Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for the use of MYCAMINE(R) (micafungin sodium) for Injection in the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses.
MYCAMINE is approved for the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses; for the treatment of patients with Esophageal Candidiasis and the prophylaxis of Candida Infections in patients undergoing Hematopoietic Stem Cell Transplantation.